Silver Oak Securities Incorporated Invests $456,000 in DexCom, Inc. (NASDAQ:DXCM)

Silver Oak Securities Incorporated acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 6,730 shares of the medical device company's stock, valued at approximately $456,000.

Several other hedge funds have also recently made changes to their positions in DXCM. Private Trust Co. NA grew its stake in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after purchasing an additional 245 shares during the last quarter. Optiver Holding B.V. acquired a new stake in shares of DexCom during the fourth quarter worth about $33,000. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% in the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after buying an additional 167 shares during the last quarter. Larson Financial Group LLC increased its holdings in DexCom by 40.5% in the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new position in DexCom in the 4th quarter worth approximately $38,000. 97.75% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have commented on DXCM. Cfra Research upgraded shares of DexCom to a "hold" rating in a research note on Friday, March 21st. Citigroup restated a "buy" rating and set a $102.00 target price (up from $82.00) on shares of DexCom in a research report on Thursday, May 22nd. Barclays increased their price target on DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Robert W. Baird decreased their price objective on DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Friday, May 2nd. Finally, Wells Fargo & Company restated an "overweight" rating on shares of DexCom in a research note on Saturday, March 8th. Four equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $98.50.

DexCom Stock Down 1.0%

DXCM stock opened at $81.01 on Friday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.32 and a current ratio of 1.50. The company's 50 day moving average price is $79.80 and its 200 day moving average price is $79.40. The firm has a market capitalization of $31.76 billion, a price-to-earnings ratio of 60.46, a PEG ratio of 1.73 and a beta of 1.46. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $117.27.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 12.90% and a return on equity of 30.05%. The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period last year, the business earned $0.32 earnings per share. The company's quarterly revenue was up 12.5% on a year-over-year basis. On average, equities research analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Sadie Stern sold 6,184 shares of the firm's stock in a transaction on Tuesday, May 27th. The stock was sold at an average price of $85.11, for a total transaction of $526,320.24. Following the transaction, the executive vice president now directly owns 109,621 shares of the company's stock, valued at approximately $9,329,843.31. This trade represents a 5.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Michael Jon Brown sold 10,000 shares of the business's stock in a transaction that occurred on Friday, May 23rd. The stock was sold at an average price of $84.28, for a total value of $842,800.00. Following the sale, the executive vice president now directly owns 95,602 shares in the company, valued at approximately $8,057,336.56. The trade was a 9.47% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,724 shares of company stock worth $2,157,034. 0.32% of the stock is owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.